Cargando…
Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation
PURPOSE: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-at-risk (OAR). However, ste...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897757/ https://www.ncbi.nlm.nih.gov/pubmed/33665480 http://dx.doi.org/10.1016/j.adro.2020.06.010 |
_version_ | 1783653731699523584 |
---|---|
author | Hassanzadeh, Comron Rudra, Soumon Bommireddy, Ani Hawkins, William G. Wang-Gillam, Andrea Fields, Ryan C. Cai, Bin Park, Justin Green, Olga Roach, Michael Henke, Lauren Kim, Hyun |
author_facet | Hassanzadeh, Comron Rudra, Soumon Bommireddy, Ani Hawkins, William G. Wang-Gillam, Andrea Fields, Ryan C. Cai, Bin Park, Justin Green, Olga Roach, Michael Henke, Lauren Kim, Hyun |
author_sort | Hassanzadeh, Comron |
collection | PubMed |
description | PURPOSE: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-at-risk (OAR). However, stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) has shown promise in delivering ablative doses safely. We sought to demonstrate the benefits of SMART using a 5-fraction approach with daily on-table adaptation. METHODS AND MATERIALS: Patients with locally advanced, nonmetastatic pancreatic adenocarcinoma were treated with 50 Gy in 5 fractions (biologically effective dose(10) 100 Gy) with a prescribed goal of 95% planning target volume coverage by 95% of prescription, prioritizing hard OAR constraints. Daily online adaptation was performed using magnetic resonance-guidance and on-table reoptimization. Patient outcomes, treatment factors, and daily adaptation were evaluated. RESULTS: Forty-four patients were treated with SMART at our institution from 2014 to 2019. Median follow-up from date of diagnosis was 16 months (range, 6.7-51.6). Late toxicity was limited to 2 (4.6%) grade 3 (gastrointestinal ulcers) and 3 (6.8%) grade 2 toxicities (duodenal perforation, antral ulcer, and gastric bleed). Tumor abutted OARs in 35 patients (79.5%) and tumor invaded OARs in 5 patients (11.1%). Reoptimization was performed for 93% of all fractions. Median overall survival was 15.7 months (95% confidence interval, 10.2-21.2), while 1-year and 2-year overall survival rates were 68.2% and 37.9%, respectively. One-year local control was 84.3%. CONCLUSIONS: This is the first reported experience using 50 Gy in 5 fractions for inoperable pancreatic cancer. SMART allows this ablative dose with promising outcomes while minimizing toxicity. Additional prospective trials evaluating efficacy and safety are warranted. |
format | Online Article Text |
id | pubmed-7897757 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-78977572021-03-03 Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation Hassanzadeh, Comron Rudra, Soumon Bommireddy, Ani Hawkins, William G. Wang-Gillam, Andrea Fields, Ryan C. Cai, Bin Park, Justin Green, Olga Roach, Michael Henke, Lauren Kim, Hyun Adv Radiat Oncol Clinical Investigation PURPOSE: Patients with inoperable pancreatic adenocarcinoma have limited options, with traditional chemoradiation providing modest clinical benefit and an otherwise poor prognosis. Stereotactic body radiation therapy for pancreatic cancer is limited by proximity to organs-at-risk (OAR). However, stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) has shown promise in delivering ablative doses safely. We sought to demonstrate the benefits of SMART using a 5-fraction approach with daily on-table adaptation. METHODS AND MATERIALS: Patients with locally advanced, nonmetastatic pancreatic adenocarcinoma were treated with 50 Gy in 5 fractions (biologically effective dose(10) 100 Gy) with a prescribed goal of 95% planning target volume coverage by 95% of prescription, prioritizing hard OAR constraints. Daily online adaptation was performed using magnetic resonance-guidance and on-table reoptimization. Patient outcomes, treatment factors, and daily adaptation were evaluated. RESULTS: Forty-four patients were treated with SMART at our institution from 2014 to 2019. Median follow-up from date of diagnosis was 16 months (range, 6.7-51.6). Late toxicity was limited to 2 (4.6%) grade 3 (gastrointestinal ulcers) and 3 (6.8%) grade 2 toxicities (duodenal perforation, antral ulcer, and gastric bleed). Tumor abutted OARs in 35 patients (79.5%) and tumor invaded OARs in 5 patients (11.1%). Reoptimization was performed for 93% of all fractions. Median overall survival was 15.7 months (95% confidence interval, 10.2-21.2), while 1-year and 2-year overall survival rates were 68.2% and 37.9%, respectively. One-year local control was 84.3%. CONCLUSIONS: This is the first reported experience using 50 Gy in 5 fractions for inoperable pancreatic cancer. SMART allows this ablative dose with promising outcomes while minimizing toxicity. Additional prospective trials evaluating efficacy and safety are warranted. Elsevier 2020-06-25 /pmc/articles/PMC7897757/ /pubmed/33665480 http://dx.doi.org/10.1016/j.adro.2020.06.010 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Clinical Investigation Hassanzadeh, Comron Rudra, Soumon Bommireddy, Ani Hawkins, William G. Wang-Gillam, Andrea Fields, Ryan C. Cai, Bin Park, Justin Green, Olga Roach, Michael Henke, Lauren Kim, Hyun Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation |
title | Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation |
title_full | Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation |
title_fullStr | Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation |
title_full_unstemmed | Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation |
title_short | Ablative Five-Fraction Stereotactic Body Radiation Therapy for Inoperable Pancreatic Cancer Using Online MR-Guided Adaptation |
title_sort | ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online mr-guided adaptation |
topic | Clinical Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897757/ https://www.ncbi.nlm.nih.gov/pubmed/33665480 http://dx.doi.org/10.1016/j.adro.2020.06.010 |
work_keys_str_mv | AT hassanzadehcomron ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT rudrasoumon ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT bommireddyani ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT hawkinswilliamg ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT wanggillamandrea ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT fieldsryanc ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT caibin ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT parkjustin ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT greenolga ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT roachmichael ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT henkelauren ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation AT kimhyun ablativefivefractionstereotacticbodyradiationtherapyforinoperablepancreaticcancerusingonlinemrguidedadaptation |